Select Page

Tigermed Insights

Home » Insights

At Tigermed, we believe knowledge needs to be shared to further develop clinical programs, increase market access, and to meet unmet patients needs. This is why we share publications, blogs and other insights here.

Hear from thought leaders and other subject matter experts on the topics, trends and market developments that are relevant to clinical trials and related areas. Remember that you are always invited to request additional information or suggest a topic you would like to learn more about. Use the contact page to reach us for any requests.

ICH Guidelines in China: Where are we now?

ICH Guidelines in China: Where are we now?

In 2017, the Chinese National Medical Products Administration (NMPA) was welcomed as a new regulatory member of the ICH. Only a year later, in June 2018, China’s health regulatory authority (National Medical Products Administration, NMPA) was elected to the ICH Management Committee, enabling the country to continue participating in international drug development and registration.

Orphan Drug Development in China

Orphan Drug Development in China

In this blog post, we will shortly outline the regulatory framework for orphan drug development in the USA and Europe, and then focus on recent developments and future prospects in China.